New triple therapy hopes to outsmart tough esophageal cancer
NCT ID NCT07531979
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of three drugs—becotatug vedotin, tislelizumab, and chemotherapy—for people with advanced esophageal squamous cell carcinoma (ESCC) who have not had prior treatment. The goal is to see if adding the targeted drug becotatug vedotin to standard immunotherapy and chemotherapy can shrink tumors better. About 93 adults with locally advanced or metastatic ESCC will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BECOTATUG VEDOTIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could essential oils tame chemo nausea? a new trial puts aromatherapy to the test
- Shielding the ovaries: a drug may help young breast cancer patients preserve fertility during chemo
- Can surgery for stomach or esophageal cancer cloud the mind?
- Art therapy meets oncology: could mandala coloring boost cancer Patients' well-being?
- Could a chemo boost after radiation tame aggressive prostate cancer?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?